Literature DB >> 19724053

How I treat EBV lymphoproliferation.

Helen E Heslop1.   

Abstract

Epstein-Barr virus (EBV)-associated B-cell lymphoproliferation is a life-threatening complication after hematopoietic stem cell or solid organ transplantation resulting from outgrowth of EBV-infected B cells that would normally be controlled by EBV-cytotoxic T cells. During the past decade, early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have helped to identify high-risk patients and to diagnose early lymphoproliferation. Treatment options include manipulation of the balance between outgrowing EBV-infected B cells and the EBV cytotoxic T lymphocyte response and targeting the B cells with monoclonal antibodies or chemotherapy. Major challenges remain for defining indications for preemptive therapies and integrating novel and conventional therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19724053      PMCID: PMC2774540          DOI: 10.1182/blood-2009-07-143545

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  66 in total

1.  Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.

Authors:  Kirsten M Williams; Meghan A Higman; Allen R Chen; Cindy L Schwartz; Moody Wharam; Paul Colombani; Robert J Arceci
Journal:  Pediatr Blood Cancer       Date:  2008-03       Impact factor: 3.167

2.  Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants.

Authors:  Richard J O'Reilly; Ekaterina Doubrovina; Deepa Trivedi; Aisha Hasan; Wouter Kollen; Guenther Koehne
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children.

Authors:  Mary M Taj; Boo Messahel; Julie Mycroft; Kathy Pritchard-Jones; Alistair Baker; Susan Height; Nedim Hadzic; C Ross Pinkerton
Journal:  Br J Haematol       Date:  2008-01       Impact factor: 6.998

4.  Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.

Authors:  Jodi M Smith; Lawrence Corey; Patrick J Healey; Connie L Davis; Ruth A McDonald
Journal:  Transplantation       Date:  2007-06-15       Impact factor: 4.939

5.  Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

Authors:  Tanzina Haque; Gwen M Wilkie; Marie M Jones; Craig D Higgins; Gillian Urquhart; Phoebe Wingate; David Burns; Karen McAulay; Marc Turner; Christopher Bellamy; Peter L Amlot; Deirdre Kelly; Alastair MacGilchrist; Maher K Gandhi; Anthony J Swerdlow; Dorothy H Crawford
Journal:  Blood       Date:  2007-04-27       Impact factor: 22.113

6.  Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.

Authors:  Ralf Trappe; Hanno Riess; Nina Babel; Manfred Hummel; Hans Lehmkuhl; Sven Jonas; Ioannis Anagnostopoulos; Matthias Papp-Vary; Petra Reinke; Roland Hetzer; Bernd Dörken; Stephan Oertel
Journal:  Transplantation       Date:  2007-04-15       Impact factor: 4.939

7.  Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.

Authors:  P Comoli; S Basso; M Zecca; D Pagliara; F Baldanti; M E Bernardo; W Barberi; A Moretta; M Labirio; M Paulli; M Furione; R Maccario; F Locatelli
Journal:  Am J Transplant       Date:  2007-06       Impact factor: 8.086

8.  Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.

Authors:  Sylvain Choquet; Stephan Oertel; Veronique LeBlond; Hanno Riess; Nathalie Varoqueaux; Bernd Dörken; Ralf Trappe
Journal:  Ann Hematol       Date:  2007-05-24       Impact factor: 3.673

9.  Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation.

Authors:  Jonathan M Cohen; Neil J Sebire; Julia Harvey; H Bobby Gaspar; Cale Cathy; Alison Jones; Kanchan Rao; David Cubitt; Persis J Amrolia; E Graham Davies; Paul Veys
Journal:  Blood       Date:  2007-05-14       Impact factor: 22.113

Review 10.  The suicide gene therapy challenge: how to improve a successful gene therapy approach.

Authors:  Chiara Bonini; Attilio Bondanza; Serena Kimi Perna; Shin Kaneko; Catia Traversari; Fabio Ciceri; Claudio Bordignon
Journal:  Mol Ther       Date:  2007-05-08       Impact factor: 11.454

View more
  100 in total

1.  Comparison of commercial extraction systems and PCR assays for quantification of Epstein-Barr virus DNA load in whole blood.

Authors:  Raphaële Germi; Julien Lupo; Touyana Semenova; Sylvie Larrat; Nelly Magnat; Laurence Grossi; Jean-Marie Seigneurin; Patrice Morand
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

2.  Monitoring of Epstein-Barr virus load in patients after allogeneic hematopoietic stem cell transplantation.

Authors:  P Volfova; M Lengerova; J Winterova; Z Racil; D Dvorakova; J Mayer
Journal:  Infection       Date:  2012-04-19       Impact factor: 3.553

Review 3.  Histone methyltransferase and histone methylation in inflammatory T-cell responses.

Authors:  Shan He; Qing Tong; Dennis Keith Bishop; Yi Zhang
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

4.  Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.

Authors:  Koen van Besien; Parameswaran Hari; Mei-Jie Zhang; Hong-Tao Liu; Wendy Stock; Lucy Godley; Olatoyosi Odenike; Richard Larson; Michael Bishop; Amittha Wickrema; Usama Gergis; Sebastian Mayer; Tsiporah Shore; Stephanie Tsai; Joanna Rhodes; Melissa M Cushing; Sandra Korman; Andrew Artz
Journal:  Haematologica       Date:  2016-02-11       Impact factor: 9.941

5.  Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience.

Authors:  Chikashi Nakanishi; Naoki Kawagishi; Satoshi Sekiguchi; Yorihiro Akamatsu; Kazushige Sato; Shigehito Miyagi; Ikuo Takeda; Daizo Fukushima; Yoshinobu Kobayashi; Kazuyuki Ishida; Hidetaka Niizuma; Shigeru Tsuchiya; Motoshi Wada; Masaki Nio; Susumu Satomi
Journal:  Surg Today       Date:  2012-01-26       Impact factor: 2.549

6.  Donor-derived second hematologic malignancies after cord blood transplantation.

Authors:  Karen K Ballen; Corey Cutler; Beow Y Yeap; Steven L McAfee; Bimalangshu R Dey; Eyal C Attar; Yi-Bin Chen; Richard L Haspel; Deborah Liney; John Koreth; Vincent Ho; Edwin P Alyea; Robert J Soiffer; Thomas R Spitzer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-21       Impact factor: 5.742

Review 7.  Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Authors:  Donald R Shaffer; Cliona M Rooney; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

8.  Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders.

Authors:  Walter J F M van der Velden; Loes Nissen; Marieke van Rijn; Jos Rijntjes; Anton de Haan; Lakshmi Venkatraman; Mark Catherwood; Hongxiang Liu; Hesham El-Daly; Lisette van de Laar; Moniek H C Craenmehr; J Han J M van Krieken; Wendy B C Stevens; Patricia J T A Groenen
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

9.  Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.

Authors:  Eric A Engels; Barbara Savoldo; Ruth M Pfeiffer; Rene Costello; Adriana Zingone; Helen E Heslop; Ola Landgren
Journal:  Transplantation       Date:  2013-02-15       Impact factor: 4.939

10.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.